Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GRITSTONE BIO, INC.

(GRTS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gritstone bio : Oncology Places 5 Million Shares for $55 Million -- Stock Down 5% After-Hours

09/16/2021 | 04:32pm EST


ę MT Newswires 2021
All news about GRITSTONE BIO, INC.
11/29Gritstone Expects 'Minimal Impact' From Omicron Variant on T Cell Epitope Constructs in..
MT
11/29The Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) C..
AQ
11/23Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
11/10Gritstone Bio Says Experimental COVID-19 Vaccine Produced Immune Response in Monkeys, M..
MT
11/10Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with..
AQ
11/10Gritstone bio, Inc. Announces Positive Preclinical Data in Non-Human Primate Challenge ..
CI
11/03Earnings Flash (GRTS) GRITSTONE BIO Posts Q3 Revenue $2.6M
MT
11/03Earnings Flash (GRTS) GRITSTONE BIO Posts Q3 Loss $-0.36
MT
11/03GRITSTONE BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
11/03Gritstone bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
More news
Analyst Recommendations on GRITSTONE BIO, INC.
More recommendations
Financials (USD)
Sales 2021 48,0 M - -
Net income 2021 -73,9 M - -
Net cash 2021 90,8 M - -
P/E ratio 2021 -12,2x
Yield 2021 -
Capitalization 897 M 897 M -
EV / Sales 2021 16,8x
EV / Sales 2022 24,2x
Nbr of Employees 188
Free-Float 96,6%
Chart GRITSTONE BIO, INC.
Duration : Period :
Gritstone bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRITSTONE BIO, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 13,20 $
Average target price 19,67 $
Spread / Average Target 49,0%
EPS Revisions
Managers and Directors
Andrew R. Allen President, Chief Executive Officer & Director
Vassiliki Celia Economides Chief Financial Officer & Executive Vice President
Elaine V. Jones Chairman
Karin Jooss Head-Research & Development
RaphaŰl Rousseau Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GRITSTONE BIO, INC.235.03%714
CSL LIMITED8.34%99 574
WUXI BIOLOGICS (CAYMAN) INC.3.31%57 915
SAMSUNG BIOLOGICS CO.,LTD.7.63%48 998
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-3.57%34 683